A new drug may soon be available for sufferers of acute coronary syndrome (ACS), according to a study in the Journal of the American Medical Association.
GlaxoSmithKline announced yesterday that clinical trials of its fondaparinux sodium product Arixtra had shown a reduction in death or recurring heart attack.
Against standard treatments, the blood-thinning drug is thought to have reduced risk of problems by 14 per cent by the end of the first month of the course.
In addition, the drug was found to offer a 13 per cent reduction in all causes of death by day nine of the trial.
The results "showed the benefit of fondaparinux for both morbidity and mortality and may prove to be a valuable treatment option for these ACS patients in the future, " said Dr Salim Yusuf, lead author of the study.
GlaxoSmithKline claims that the product has few side effects, with no increased risk of strokes or bleeding.
The company is expected to file their findings with regulatory authorities over the coming months.